For instance, MYC is amplified in up to 78% of osteosarcomas, 65% of ovarian serous cystadenocarcinomas, 48% of breast cancers, 45% of esophageal cancers and 37% of lung squamous cell carcinomas (167). This evidence concerns the gene MYC and osteosarcoma.